There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society.
See the full list of benefits that ESMO members enjoy including access to OncologyPRO, subscription to Annals of Oncology and reduced meeting registration fees
A unique networking resource for ESMO members wishing to contact one another.
We have a network of National and Regional Representatives who act as ambassadors of ESMO’s mission in their respective country or region
The member panel gives feedback on ESMO products and services through the completion of regular online surveys. Would you like to contribute?
ESO ESMO Advanced Breast Cancer • Primary Breast Cancer • BRCA in Breast Cancer
High-Grade Malignant Glioma
Adrenal cancer • Thyroid cancer
Anal Cancer • Metastatic Colorectal Cancer • Oesophageal Cancer • Gastric Cancer • Early Colon Cancer • Familial Risk Colorectal Cancer • Rectal Cancer • Pancreatic Adenocarcinoma • Hepatocellular Carcinoma • Biliary Cancer
Bladder Cancer • Renal Cell Carcinoma • Prostate Cancer • Penile Carcinoma • Testicular Seminoma and Non-Seminoma
Endometrial Cancer • Gestational Trophoblastic-Disease • Newly-Diagnosed and Relapsed Epithelial Ovarian Carcinoma • Non-Epithelial Ovarian Cancer
New for 2014! Myelodysplastic Syndromes Clinical Practice Guideline, download your copy now along with the updated guideline on Follicular Lymphoma
The ESMO Clinical Practice Guidelines on Squamous cell carcinoma of the head and neck and Nasopharyngeal cancer include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.
Our latest 2014 update of the Metastatic non-small-cell lung cancer (NSCLC) Clinical Practice Guideline has just been published
The ESMO Clinical Practice Guidelines on Melanoma currently focus on cutaneous melanoma and include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.
ESMO has two Clinical Practice Guidelines on Neuroendocrine Tumours: Neuroendocrine bronchial and thymic tumours and Neuroendocrine gastroenteropancreatic tumours. They include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.
The ESMO Clinical Practice Guidelines on Sarcoma and GIST are the result of a consensus conference held every two years which brings together a large group of European experts. Topics covered are: Soft tissue and visceral sarcomas, Bone sarcomas and Gastrointestinal stromal tumours.
The updated version of the Cancer, pregnancy and fertility Guideline is now available!
Download the new version of our App with the latest Pocket Guidelines for professionals and Guides for Patients
All webcasts and presentations from #ESMO14 are now online!
The 6th European Multidisciplinary Meeting on Urological Cancers will be held in Lisbon, Portugal. 13-16 November 2014
Join us in Geneva, Switzerland. 21-22 November 2014
Join ESMO, ESTRO and EHNS in Nice, France. 12-14 Feb 2015
Save the date for the symposium: 6 March 2015 in Valencia, Spain
Join us in Barcelona, Spain for Signalling Pathways 2015. 13-14 March 2015
Join EORTC, EANO & ESMO for this conference in Istanbul, Turkey. 27-28 March 2015
Save the date for ELCC 2015. Geneva, Switzerland; 15-18 April 2015
Save the date for the IMPAKT 2015 breast cancer conference: 7-9 May 2015
The 2015 ESMO World Congress on Gastrointestinal Cancer will place from 1-4 July 2015 in Barcelona, Spain
Join us for this new course for medical oncologists: 28-30 Aug 2015, Oxford, UK
Save the date for the European Cancer Congess 2015: Vienna, Austria, 25-29 September 2015
The first ESMO Asia congress will take place in Singapore, 18-21 December 2015
Last chance to apply for a travel grant to attend the 2014 ESMO Preceptorship on Immunotherapy of Cancer. Deadline: 27 October 2014
View the complete list of ESMO oncology conferences including partnership, labelled and supported meetings.
Access information and reports from past ESMO events
Addressing the daily needs of ESMO young oncologists
Invest in your future and the future of cancer care. Learn more about our Oncology Fellowship Programme.
The latest oncology jobs can be found here, including information on how to post a job.
The winners of the 2014 ESMO Awards, were presented during the opening ceremony at ESMO 2014 Congress in Madrid, Spain
The Recommendations are a set of guidelines with for clinical training in medical oncology. The 2010 update is now available in Portuguese.
ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.
The ESMO examination is a valuable assessment tool for practising medical oncologists and an excellent opportunity for medical oncologists in training to assess their knowledge
If you’ve already sat the ESMO exam, then take a look at our CME opportunities.
Discover the results of the ESMO Survey on the challenges faced by female oncologists
Most ESMO Cancer Guides for Patients are now available in Greek. Download your copy now!
Now available in Greek, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.
The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.
Read the reports from the ESMO/EAPC opioid survey and the oncologist/patient communication survey.
An integral part of our mission is to keep patients informed about the latest advances in cancer care.
The ESMO Patient Track encourages communication between patients, families, oncologists and healthcare professionals.
Medical oncology is included among the medical specialities covered by the European Commission Directive 2005/36/EC.
ESMO’s political initiatives aim to promote the profession of medical oncology and keep cancer policy high on the European healthcare agenda.
ESMO position statements and recommendations can be downloaded here.
Rare Cancers Europe is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda.
The objective of this ESMO-led study is to provide European health authorities with data on the availability of licensed anti-neoplastic medicines across Europe
ESMO has endorsed the 'Prague Charter: Relieving suffering' set up by the European Association for Palliative Care (EAPC) & other organisations
ESMO seeks to eradicate cancer at its earliest stages through effective cancer prevention awareness and advocacy campaigns.